All articles tagged with #lynch syndrome
Researchers are developing vaccines that train the immune system to recognize and attack Lynch syndrome–related precancers, potentially preventing colorectal cancer in high-risk individuals; early trials (Nouscom, with follow-ons from Moderna and ImmunityBio) show the approach can boost tumor-fighting T cells and reduce precancerous growths, with larger U.S. and Britain studies planned.
Researchers are testing vaccines designed to train the immune system to recognize and destroy precancerous Lynch syndrome–driven cells, with early trials showing reduced precancerous polyps and polyp-free colonoscopies in some participants. Several vaccines are in development (Nouscom in the US/UK, Moderna via Oxford, ImmunityBio) aiming to prevent colorectal cancer before it starts, potentially reducing the need for yearly colonoscopies for high-risk individuals. Results are early but promising for those with inherited cancer risk and their families.
A phase 1 trial by Oxford and Moderna is testing an mRNA vaccine (INTERCEPT – Lynch) designed to help the immune system identify and eliminate very early cancer changes in people with Lynch syndrome, potentially shifting care from treatment to prevention; the first participant, Sarah Ewart, marks a step toward validating safety and immune response with a plan to move to phase 2 across UK centres if successful.
A 33-year-old nurse dismissed intermittent blood in her stool for years, attributing it to hemorrhoids, until a 2019 gastroenterology visit revealed stage 3 colon cancer with lymph node involvement. She underwent surgery to remove part of her colon and 13 lymph nodes, then completed concurrent chemotherapy while continuing to work. Months after finishing treatment, she became pregnant; genetic testing later diagnosed Lynch syndrome, an inherited cancer risk. Now in remission, she undergoes yearly surveillance and has used her platform—including winning the 2024 Mrs. Mississippi Plus America pageant—to advocate for colon cancer awareness, screening, and genetic testing for family members.
New trials and analyses indicate daily aspirin—especially at low doses (75–100 mg)—can significantly reduce colorectal cancer risk in high-risk groups like Lynch syndrome, with evolving evidence that this benefit may extend to other cancers. Guideline updates in the UK and Sweden reflect confidence in targeted use, but experts caution that aspirin’s risks (bleeding, ulcers) require medical supervision and that research continues to clarify mechanisms (Cox-2 and thromboxane pathways) and optimal dosing.
A 46-year-old Ohio factory worker mistook painful bathroom symptoms for hemorrhoids until his wife noticed bloodshot eyes, which led to a diagnosis of a rare, highly aggressive colorectal cancer called hepatoid adenocarcinoma linked to Lynch syndrome. Diagnosed at stage 3, he underwent eight weeks of radiation and immunotherapy, avoided chemotherapy due to his genetic mutation, and showed a strong treatment response with plans for continued immunotherapy and surveillance—highlighting the importance of genetic testing in early-onset cancers.
A Charlotte woman, 49, who felt exhausted for months underwent a colonoscopy that found a large rectal tumor, diagnosed as Stage 3C cancer; after chemotherapy, radiation and multiple surgeries she is now cancer-free, underscoring the importance of early screening to detect colorectal cancer before it progresses.
Healthy 37-year-old Mohammad Samad experienced abdominal pain, bloating, and constipation that were misattributed to stress, IBS, and Crohn’s disease, delaying a diagnosis of stage-3 colon cancer. After a colonoscopy confirmed the tumor, he underwent chemotherapy and emergency surgery when infections prevented further treatment, the tumor grew to the size of a watermelon, and he required a stoma and nerve damage. He is now cancer-free for two years, with his tumor testing positive for Lynch syndrome, and he has launched a blog to raise awareness about rising cancer rates among young people and the need for earlier screening and awareness.
A phase 1b/2 trial of a preventive cancer vaccine for Lynch syndrome carriers, including Kevin Heyink, showed the vaccine is safe and elicits a lasting immune response. In a 45-participant trial, vaccinated individuals had fewer precancerous lesions and no advanced tumors; Heyink has since had three cancer-free colonoscopies in a row. The vaccine uses a modified adenovirus to train the immune system to recognize Lynch-related proteins, offering hopeful potential to reduce cancer risk, though larger trials are needed before wider use.
A 79-year-old woman with Lynch syndrome is uncertain about continuing colonoscopies due to her age and cardiac risks. Dr. Roach explains that the decision to stop screening depends on individual health and risk factors, noting her lifetime colon cancer risk is about 20%, but her risk decreases with age. Both risks are low, so stopping is reasonable if she prefers, but continuing is also acceptable.
Diane Davis's advanced ovarian cancer was initially thought incurable until molecular testing revealed she had Lynch syndrome, a genetic condition that made her cancer more responsive to immunotherapy, leading to a complete remission and highlighting the importance of genetic testing in cancer treatment.
A woman with advanced ovarian cancer was saved by identifying her rare genetic condition, Lynch syndrome, through molecular testing, which led to effective immunotherapy treatment and a significant remission, highlighting the importance of genetic diagnosis in cancer treatment.
A Newcastle University-led study found that a low dose of 75mg aspirin is as effective as higher doses in reducing cancer risk in patients with Lynch syndrome, potentially leading to updated medical recommendations for this genetic condition.
A long-term study shows that consuming resistant starch, found in green bananas, oats, and pulses, can reduce the risk of various cancers in people with Lynch syndrome by over 60%, especially targeting hard-to-diagnose upper GI cancers, highlighting the potential of dietary changes in cancer prevention.
Lynch syndrome is a little-known genetic disorder that greatly increases the risk of various cancers, including colon, colorectal, uterine, ovarian, stomach, small bowel, kidney, bladder, and brain cancer. Due to its silent nature, 95% of patients with the condition are unaware of it until they develop cancer. Genetic testing through blood or saliva tests can diagnose Lynch syndrome, and those who test positive should undergo regular screenings, especially colonoscopies, to monitor for cancer. A clinical trial for a new cancer vaccine targeting Lynch syndrome patients is underway, with the potential to extend to other types of cancers if successful. It's crucial for individuals to discuss their family history with their primary care doctors and consider genetic testing, as early detection can lead to more frequent screenings and potentially life-saving interventions.